These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 32531478)

  • 1. Lemborexant vs suvorexant for insomnia: A systematic review and network meta-analysis.
    Kishi T; Nomura I; Matsuda Y; Sakuma K; Okuya M; Ikuta T; Iwata N
    J Psychiatr Res; 2020 Sep; 128():68-74. PubMed ID: 32531478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial.
    Yardley J; Kärppä M; Inoue Y; Pinner K; Perdomo C; Ishikawa K; Filippov G; Kubota N; Moline M
    Sleep Med; 2021 Apr; 80():333-342. PubMed ID: 33636648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Lemborexant in Adults ≥ 65 Years of Age with Insomnia Disorder.
    Arnold V; Ancoli-Israel S; Dang-Vu TT; Mishima K; Pinner K; Malhotra M; Moline M
    Neurol Ther; 2024 Aug; 13(4):1081-1098. PubMed ID: 38748321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of lemborexant versus placebo and zolpidem: effects on auditory awakening threshold, postural stability, and cognitive performance in healthy older participants in the middle of the night and upon morning awakening.
    Murphy P; Kumar D; Zammit G; Rosenberg R; Moline M
    J Clin Sleep Med; 2020 May; 16(5):765-773. PubMed ID: 32022664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of lemborexant in midlife women with insomnia disorder.
    Terauchi M; Cheng JY; Yardley J; Pinner K; Moline M; Malhotra M; Inabe K; Nishida M; Pappadopulos E
    Menopause; 2023 Aug; 30(8):839-848. PubMed ID: 37339396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.
    Rosenberg R; Murphy P; Zammit G; Mayleben D; Kumar D; Dhadda S; Filippov G; LoPresti A; Moline M
    JAMA Netw Open; 2019 Dec; 2(12):e1918254. PubMed ID: 31880796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of lemborexant treatment on insomnia severity: analyses from a 12-month study of adults with insomnia disorder.
    Roth T; Rosenberg R; Morin CM; Yardley J; Pinner K; Perdomo C; Atkins N; Pappadopulos E; Malhotra M; Moline M
    Sleep Med; 2022 Feb; 90():249-257. PubMed ID: 35220140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2.
    Kärppä M; Yardley J; Pinner K; Filippov G; Zammit G; Moline M; Perdomo C; Inoue Y; Ishikawa K; Kubota N
    Sleep; 2020 Sep; 43(9):. PubMed ID: 32585700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.
    Kishi T; Matsunaga S; Iwata N
    PLoS One; 2015; 10(8):e0136910. PubMed ID: 26317363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Lemborexant in Patients With Irregular Sleep-Wake Rhythm Disorder and Alzheimer's Disease Dementia: Results From a Phase 2 Randomized Clinical Trial.
    Moline M; Thein S; Bsharat M; Rabbee N; Kemethofer-Waliczky M; Filippov G; Kubota N; Dhadda S
    J Prev Alzheimers Dis; 2021; 8(1):7-18. PubMed ID: 33336219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of lemborexant in subjects previously treated with placebo for 6 months in a randomized phase 3 study.
    Yardley J; Inoue Y; Pinner K; Perdomo C; Kubota N; Perlis ML; Moline M
    Sleep Med; 2023 Oct; 110():111-119. PubMed ID: 37574610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis.
    McElroy H; O'Leary B; Adena M; Campbell R; Monfared AAT; Meier G
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1296-1308. PubMed ID: 34121443
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of discontinuation of lemborexant following long-term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial.
    Takaesu Y; Suzuki M; Moline M; Pinner K; Inabe K; Nishi Y; Kuriyama K
    Clin Transl Sci; 2023 Apr; 16(4):581-592. PubMed ID: 36564964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and safety of lemborexant 5 mg versus 10 mg for the treatment of insomnia: a systematic review.
    Habiba U; Waseem R; Shaikh TG; Waseem S; Ahmed SH; Asghar MS
    Neurol Sci; 2023 May; 44(5):1533-1541. PubMed ID: 36633778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.
    Michelson D; Snyder E; Paradis E; Chengan-Liu M; Snavely DB; Hutzelmann J; Walsh JK; Krystal AD; Benca RM; Cohn M; Lines C; Roth T; Herring WJ
    Lancet Neurol; 2014 May; 13(5):461-71. PubMed ID: 24680372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.
    De Crescenzo F; D'Alò GL; Ostinelli EG; Ciabattini M; Di Franco V; Watanabe N; Kurtulmus A; Tomlinson A; Mitrova Z; Foti F; Del Giovane C; Quested DJ; Cowen PJ; Barbui C; Amato L; Efthimiou O; Cipriani A
    Lancet; 2022 Jul; 400(10347):170-184. PubMed ID: 35843245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled, crossover study of respiratory safety of lemborexant in moderate to severe obstructive sleep apnea.
    Cheng JY; Lorch D; Lowe AD; Uchimura N; Hall N; Shah D; Moline M
    J Clin Sleep Med; 2024 Jan; 20(1):57-65. PubMed ID: 37677076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement in fatigue and sleep measures with the dual orexin receptor antagonist lemborexant in adults with insomnia disorder.
    Chepke C; Jain R; Rosenberg R; Moline M; Yardley J; Pinner K; Kumar D; Perdomo C; Filippov G; Atkins N; Malhotra M
    Postgrad Med; 2022 Apr; 134(3):316-325. PubMed ID: 35254948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of insomnia treatment with lemborexant in older adults: analyses from three clinical trials.
    Gotfried MH; Auerbach SH; Dang-Vu TT; Mishima K; Kumar D; Moline M; Malhotra M
    Drugs Aging; 2024 Sep; 41(9):741-752. PubMed ID: 39120786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis.
    Xue T; Wu X; Li J; Chen S; Wang Z; Tan X; Wang Z; Zhang J
    Front Pharmacol; 2023; 14():1175372. PubMed ID: 37261282
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.